Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Fragment Based Drug Discovery of Novel MK2 Inhibitors

Thomas Hesterkamp, VP Fragment Based Drug Discovery, Evotec AG, speaking at MedChem Europe 2009
Date Posted: Thursday, November 19, 2009
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec and Dow AgroSciences Collaborate on Cellular Target Profiling
Collaboration has objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences.
Tuesday, July 09, 2013
Evotec Extends Ongoing Collaboration with CHDI Foundation
Collaboration aims to accelerate development of drugs that slow the progression of Huntington's disease.
Monday, November 05, 2012
Evotec and Bayer Enter into Multi-target Alliance to Fight Endometriosis
Companies have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.
Monday, October 01, 2012
Evotec and IR Pharma Establish Drug Discovery Alliance
Companies have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.
Thursday, February 16, 2012
Evotec and Merck KGaA to Collaborate on Neurological Disease Target
Evotec to apply integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target.
Wednesday, November 24, 2010
Evotec and APEIRON Biologics build Pain Alliance
The collaboration will initially identify small molecule modulators of DREAM - Downstream Regulatory Element Antagonistic Modulator.
Monday, November 01, 2010
Evotec Licenses Phase II Insomnia Candidate to Jingxin Pharma for Development in China
Jingxin Pharma will initiate clinical trials with EVT 201 in China in 2011.
Monday, November 01, 2010
Evotec Completes Acquisition of DeveloGen
The transaction adds two complementary alliances - one with Boehringer Ingelheim and one with Andromeda to Evotec's portfolio of core assets.
Friday, September 03, 2010
Evotec Earns Milestone in Oncology Programme as Part of its Research Alliance with Boehringer Ingelheim
The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.
Thursday, June 17, 2010
Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
Evotec receives EUR 2.0M milestone payment with initiation of the Phase I clinical studies for the compound.
Thursday, May 20, 2010
Scientific News
Laser Technique for Self-Assembly of Nanostructures
Researchers have developed a low-cost technique that holds promise for a range of scientific and technological applications.
Researcher Discovers Molecules That Kill Cancer, Protect Healthy Cells
This research shines a light on what happens to cells at the moment they become cancerous and the potential of femtomedicine to revolutionize cancer treatment.
Label-Free Binding Analysis Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Progress Towards A New Asthma Treatment
University of Queensland researchers are developing a new asthma treatment that targets the underlying cause of asthma, rather than just the symptoms.
Multiple Types Of Resistance To New Lung Cancer Drug Identified
Study shows genomic heterogeneity in mechanisms of resistance to TKI drugs.
Compound To Combat Malaria Parasite Identified
Study identifies non-mevalonate pathway for isoprenoid biosynthesis as key antimalarial drug target.
Are Chemical Safety Regulations Changing Your Laboratory?
GHS changes to country chemical regulations affect everyone.
Drugs that Activate Brain Stem Cells May Reverse Multiple Sclerosis
NIH-funded study identifies over-the-counter compounds that may replace damaged cells.
Allergy Drug Inhibits Hepatitis C in Mice
NIH study suggests alternative drug to treat virus.
Saccharin Shows Promise as Cancer Inhibitor
Researchers have found that the artificial sweetener can inhibit cancer cell growth.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters